Applying growth hormone as an adjuvant to correct poor prognosis outcomes in IVF: Study 1 compares melatonin

This retrospective study examines the influence of recombinant growth hormone (rGH) and melatonin adjuvants on oocyte numbers, embryo utilization live births arising from 3637 autologous IVF±ICSI treatment cycles undertaken 2376 women across ten years (2011-2020) within a pioneer Australian facility. Despite using an FSH-dosing algorithm enabling maximal doses up to 450 IU for with reduced ovarian reserve, younger had significantly higher mean numbers oocytes recovered than older ranging 11.1 <35 9.4 aged 35-39 reducing 6.5 40-44 4.0 those ?45 (p<0.0001). Overall, rate was 48.5% birth productivity 35.4 % all ages neither rGH nor showed any benefit these rates, in fact, nil highest per initiated cycle (42.0% overall: p<0.0001, 55.3% youngest group: p<0.001). Embryo increased marginally by who high reserve (p<0.05), but this did not translate into improvement rate. Similarly, other factors known cause poor prognosis, including low IGF-1 profile, recurrent implantation failure, at OPU, no adjuvants. The relevance quality examined 1135 whose residual embryos after single fresh-embryo transfer failed develop suitable grade cryopreservation. From 1727 such often displayed improved rGH, melatonin. Even so, rates were either